About Us

FSD Pharma, Inc. is a publicly traded holding company, since May 2018.

FSD BioSciences, Inc., a wholly-owned subsidiary, is a specialty biotech pharmaceutical R&D company focused on developing over time multiple applications of its lead compound, FSD201 ultra-micronized Palmitoyl ethylamine (PEA). Ultra-Micro PEA is known to target the CB2 receptors of the endocannabinoid system of the human body and acts by down-regulating the pro-inflammatory cytokines to effectuate an anti-inflammatory response.

Our Mission

We are a specialty pharmaceutical research and development company focused on developing FDA approved prescription medications to deliver better treatment outcomes and produce positive and sustainable shareholder value.